Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma

• Published in: Current opinion in oncology Vol. 32; no. 5; p. 418
• Main Authors: Beauvais, David, Danhof, Sophia, Hayden, Patrick J, Einsele, Hermann, Yakoub-Agha, Ibrahim
• Format: Journal Article
• Language: English
• Published: United States 01.09.2020
• Subjects: Antigens, CD19 - immunology; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Immunotherapy, Adoptive - methods; Multiple Myeloma - immunology; Multiple Myeloma - therapy; Receptors, Antigen, T-Cell - genetics; Receptors, Antigen, T-Cell - immunology; Receptors, Chimeric Antigen - genetics; Receptors, Chimeric Antigen - immunology

Despite considerable therapeutic advances over the last decade, multiple myeloma remains an incurable disease. Novel treatment strategies are urgently needed. T cells can be genetically modified to express chimeric antigen receptors (CARs) targeting defined surface antigens on tumor cells. To date,...